Eindhoven, North Brabant, Netherlands
Bram Ramaekers, PhD is a senior researcher in Clinical Epidemiology and Health Technology Assessment at Maastricht University Medical Center+ (MUMC+) and CAPHRI, Maastricht University. His work focuses on decision-analytic modelling to inform health policy and reimbursement decisions, with expertise in cost-effectiveness analysis, survival modelling, structural uncertainty, and patient heterogeneity. He has extensive experience leading model-based economic evaluations across oncology, medical technologies, and digital health, and regularly acts as health-economic lead in national and international assessment processes. As health-economic lead within a NICE External Assessment Group, he has contributed to more than 50 NICE technology appraisals. He was co-author of the 2016 Dutch guideline for health economic evaluations and contributes to ongoing methodological development, including tools for survival model selection and structural uncertainty assessment (e.g., the PERSUADE R package). Bram is actively involved in policy advisory programmes, including initiatives of the Dutch Health Care Institute, and leads health-economic work packages within national and EU-funded research consortia. He co-supervises multiple PhD candidates and has co-supervised six PhD students to completion. His research aims to strengthen the robustness, transparency and policy relevance of health technology assessment.
Main topic: the role of patient heterogeneity in Health Technology Assessment
Examining the cost-effectiveness of proton radiothearpy for head and neck cancer patients.